| Date Filed | Type | Description |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/28/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/13/2023 |
SC 13G
| Schindel Yair Chaim reports a 6% stake in Akoya Biosciences, Inc. |
| 06/12/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 06/09/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"2 Akoya Disclaimer Disclaimer Akoya Biosciences, Inc. has filed a registration statement with the Securities Exchange Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, including the preliminary prospectus supplement, and other documents the Company has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone at 1-866-718-1649 or by ..." |
|
| 06/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/08/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/20/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/20/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/20/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/06/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| PSC Capital Partners LLC reports a 7.2% stake in Akoya Biosciences, Inc. |
| 02/07/2023 |
SC 13D/A
| Hudson Executive Capital LP reports a 5% stake in Akoya Biosciences, Inc. |
| 12/02/2022 |
SC 13D/A
| Hudson Executive Capital LP reports a 6.4% stake in Akoya Biosciences, Inc. |
| 11/22/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/07/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 11/07/2022 |
8-K
| Quarterly results |
| 09/13/2022 |
SC 13D/A
| Hudson Executive Capital LP reports a 9.8% stake in Akoya Biosciences, Inc. |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
8-K
| Quarterly results |
| 06/02/2022 |
8-K
| Quarterly results |
|